<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03431571</url>
  </required_header>
  <id_info>
    <org_study_id>V1601CI</org_study_id>
    <nct_id>NCT03431571</nct_id>
  </id_info>
  <brief_title>Use of the VisuMax Femtosecond Laser Lenticule Removal Procedure for the Correction of Hyperopia</brief_title>
  <acronym>V1601CI</acronym>
  <official_title>Use of the VisuMax Femtosecond Laser Lenticule Removal Procedure for the Correction of Hyperopia With or Without Astigmatism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carl Zeiss Meditec AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carl Zeiss Meditec AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The correction of farsightedness using ReLEx SMILE for hyperopia is focus of this
      investigation. The objective is to evaluate the safety and effectiveness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The VisuMax laser keratome is an ophthalmic surgical femtosecond laser intended for use in
      patients requiring corneal incisions. The cutting action of the VisuMax laser keratome is
      achieved through precise individual micro-photodisruptions of tissue, created by tightly
      focused, ultra-short pulses, delivered through a disposable applanation lens while fixating
      the eye under a low vacuum. ReLEx SMILE combines state-of-the-art femtosecond laser
      technology of the VisuMax with high-precision lenticule extraction to provide minimally
      invasive refractive correction. It is distinguished by its flapless, minimally invasive laser
      correction. A refractive lenticule is created in the intact cornea, but removed via a small
      incision. The changed form of the cornea corrects the refraction error. ReLEx SMILE for
      myopia is a well-established treatment with extensive supporting published evidence for
      efficacy and safety. It is CE marked and available since 2011; more than 1 Million procedures
      have been performed worldwide. The correction of farsightedness using ReLEx SMILE for
      hyperopia is focus of this investigation and is therefore not yet CE marked.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corrected Distance Visual Acuity (CDVA)</measure>
    <time_frame>12 months</time_frame>
    <description>CDVA in logMar</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>side effects</measure>
    <time_frame>12 months</time_frame>
    <description>distribution in percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>contrast sensitivity</measure>
    <time_frame>12 months</time_frame>
    <description>contrast sensitivities for all spatial frequencies (3, 6, 12 and 18 cpd) in logMar</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient satisfaction (Quality of Vision Questionnaire)</measure>
    <time_frame>12 months</time_frame>
    <description>Mean +/- standard deviation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>manifest refractive astigmatism</measure>
    <time_frame>12 months</time_frame>
    <description>Astigmatism in diopters [D]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>spherical equivalent (SE)</measure>
    <time_frame>12 months</time_frame>
    <description>SE in diopters [D]</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">374</enrollment>
  <condition>Hypermetropia</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>ReLEx SMILE treatment can be done binocular or monocular, no masking and randomization used, no control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ReLEx SMILE</intervention_name>
    <description>the VisuMax femtosecond laser is used to cut a thin layer of corneal tissue that is removed through a small cut in the cornea</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal corneal topography;

          -  Predicted post-operative keratometry ≤51 D;

          -  Contact lens wearers must stop wearing their contact lenses before baseline
             measurements according to local requirements of the clinic;

          -  Patients should be able to understand the patient information and willing to sign an
             informed consent;

          -  Patients should be willing to comply with all follow-up visits and the respective
             examinations;

          -  Patients with hyperopia or hyperopia with astigmatism (attempted correction: sphere up
             to +6.00D, cylinder up to 5.00D and maximum hyperopic meridian up to +7.00D);

          -  The corrected distance visual acuity should be 20/25 or better in each eye
             pre-operatively;

          -  A difference between cycloplegic and manifest refractions of ≤1.00 D spherical
             equivalent in the eye to be treated;

        Exclusion Criteria:

          -  The patients presenting at least one of the characteristics as described for exclusion
             criteria in the documentation set of the VisuMax laser keratome ReLEx SMILE option.

          -  Mixed astigmatism

          -  Any impaired person (minors, pregnant or breast feeding women or persons incapable of
             giving consent) are definitely excluded from the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Sekundo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uniklinikum Gießen Marburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jana Gehmlich</last_name>
    <phone>+493641220347</phone>
    <email>jana.gehmlich@zeiss.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Center Shanghai</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Zhou Xingtao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Eye Hospital, Heping District</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wang Yan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gemini Eye Clinic</name>
      <address>
        <city>Zlín</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pavel Stodulka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center CHRU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Beatrice Cochener</last_name>
    </contact>
    <investigator>
      <last_name>Beatrice Cochener</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center Heliosklinikum</name>
      <address>
        <city>Erfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcus Blum</last_name>
    </contact>
    <investigator>
      <last_name>Marcus Blum, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Universitätsklinikum Gießen Marburg</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Sekundo</last_name>
      <phone>+49 6421586 6275</phone>
    </contact>
    <investigator>
      <last_name>Walter Sekundo, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center Nethradhama Superspeciality Eye Hospital</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sri Ganesh</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>London Vision Clinic</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dan Reinstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2018</study_first_submitted>
  <study_first_submitted_qc>February 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2018</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ReLEx</keyword>
  <keyword>SMILE</keyword>
  <keyword>Hyperopia</keyword>
  <keyword>VisuMax</keyword>
  <keyword>Small Incision Lenticule Extraction</keyword>
  <keyword>Lenticule</keyword>
  <keyword>Farsightedness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

